Institutional Ownership
Lb Pharmaceuticals Inc
CUSIP 50180M108COM SHSLBRXQ1 2026
13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
14.9%
Max % of class reported
Institutional Holders
73
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
12 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Ra Capital Management, L.P. | 13G/A | 8.7% | 2.21M | SEC |
| 2 | Feb 10, 2026 | Deep Track Biotechnology Master Fund, Ltd. | 13D/A | 11.7% | — | SEC |
| 3 | Jan 21, 2026 | Blackrock Portfolio Management LLC | 13G/A | 3.8% | 961.2K | SEC |
| 4 | Jan 21, 2026 | Blackrock, Inc. | 13G | 5.1% | 1.28M | SEC |
| 5 | Jan 21, 2026 | Jpmorgan Chase &Amp; Co. | 13G | 6.3% | 1.61M | SEC |
| 6 | Dec 31, 2025 | Trails Edge Capital Partners, LP | 13G | 5.0% | 1.27M | SEC |
| 7 | Oct 17, 2025 | Blackrock Portfolio Management LLC | 13G | 5.9% | 975.0K | SEC |
| 8 | Sep 25, 2025 | Pontifax Management 4 G.P. (2015) Ltd. | 13D | 6.3% | — | SEC |
| 9 | Sep 19, 2025 | Ra Capital Management, L.P. | 13G | 7.5% | 1.68M | SEC |
| 10 | Sep 19, 2025 | Deep Track Biotechnology Master Fund, Ltd. | 13D | 14.9% | — | SEC |
2 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Lb Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Deep Track Capital, LP | 3.35M | $82.68M |
| 2 | Blackrock, Inc. | 2.47M | $60.93M |
| 3 | Ra Capital Management, L.P. | 2.21M | $54.46M |
| 4 | Tcg Crossover Management, LLC | 1.84M | $45.28M |
| 5 | Commodore Capital LP | 1.50M | $36.99M |
| 6 | Caligan Partners LP | 1.44M | $34.63M |
| 7 | Spruce Street Capital LP | 1.38M | $33.64M |
| 8 | Jpmorgan Chase & Co | 1.43M | $33.19M |
| 9 | Trails Edge Capital Partners, LP | 1.32M | $32.54M |
| 10 | Nantahala Capital Management, LLC | 1.05M | $25.96M |